Endeavor BioMedicines Partners With XCures To Identify Patients With PTCH1 Mutations For Phase 2 Trial Of ENV-101 (Taladegib) by Seini Moimoi | May 31, 2022 | Portfolio News
Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator by Seini Moimoi | May 31, 2022 | Portfolio News
Endeavor Doses First Patient In Phase 2 Oncology Study Evaluating The Safety And Efficacy Of ENV-101 (Taladegib) by Seini Moimoi | May 25, 2022 | Portfolio News
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update by Seini Moimoi | May 16, 2022 | Uncategorized, Portfolio News
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update by Seini Moimoi | May 12, 2022 | Portfolio News
89bio Reports First Quarter 2022 Financial Results and Provides Corporate Update by Seini Moimoi | May 11, 2022 | Portfolio News
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update by Seini Moimoi | May 5, 2022 | Portfolio News
Axonics® Reports First Quarter 2022 Financial Results by Seini Moimoi | May 5, 2022 | Portfolio News
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types by Seini Moimoi | Apr 19, 2022 | Portfolio News
